Entyvio 300 MG vials
Ended Awarded
- Contract number
- SPE2DB25FC1FX
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $29,670
Award facts
- Contract value 100% obligated
- $29,669.58 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $29,669.58 to DMS Pharmaceutical Group Inc. for the supply of Entyvio 300 mg vials. This delivery order, issued on July 14, 2025, with an ultimate completion date of August 4, 2025, was awarded without a set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform the delivery from its Park Ridge location. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, a $500 million vehicle valid through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products supporting military healthcare facilities.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain through consistent contract awards with the DLA. The company specializes in distributing branded and generic prescription drugs, biologics, and medical consumables to Department of Defense healthcare sites nationwide. Entyvio, a biologic medication used in the treatment of inflammatory bowel disease, represents one of the specialized pharmaceutical products within the company's extensive delivery portfolio under its IDC. The firm fixed-price structure ensures cost certainty for this critical pharmaceutical supply to federal healthcare operations.
Quick answers
Who was awarded contract SPE2DB25FC1FX?
SPE2DB25FC1FX was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on July 14, 2025.
How much is contract SPE2DB25FC1FX worth?
The government has obligated $29,670 on SPE2DB25FC1FX.
Is contract SPE2DB25FC1FX an order under another contract?
Yes. SPE2DB25FC1FX is a delivery order under SPE2DB20D9766, an indefinite delivery contract.
Was contract SPE2DB25FC1FX competed?
The extent of competition for SPE2DB25FC1FX was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award